Accordingly, we found that combined inhibition of MET and FGFR in a basal B PDX resulted in a decrease in sphere-forming and CD44+CD24−/low populations, indicative of a loss of TICs and reduction in overall tumour burden. The gene discussed is MET; the disease is neoplasm.